Development of ultrasound based molecular imaging in an attempt to predict early response of antiangiogenic therapy

我们进行了一项研究，以确定对比增强超声（CE US）作为接受索拉非尼治疗的晚期肝细胞癌（HCC）患者预后工具的效用，并确定与早期治疗反应相关的CE US参数。因此，CE - US可用于量化HCC患者在索拉非尼治疗后数天内肿瘤血管的动态变化。这些肿瘤灌注的早期变化可能预测1个月时的肿瘤反应，它们可能是HCC患者抗血管生成治疗有效性的潜在替代指标。

We conducted a study to determine the utility of contrast-enhanced ultrasonography (CE US) as a prognostic tool for advanced hepatocellular carcinoma (HCC) patients receiving sorafenib and to identify CE US parameters that correlate with early treatment response. As a results, CE US can be used to quantify dynamic changes in tumor vascularity as early as several days after sorafenib administration in patients with HCC. These early changes in tumor perfusion may be predictive of tumor response at 1 month, and they may be potential surrogate measures of the effectiveness of antiangiogenic therapy in patients with HCC.